Valeant
Pharmaceuticals International Inc. (NYSE: VRX) will acquire Salix Pharmaceuticals Ltd. (Nasdaq:
SLXP) in a cash deal valued at approximately $14.5 billion. Valeant
also reported sharply higher fourth quarter earnings that topped analyst
estimates as revenue rose. Shares of Valeant leaped $23.24 to $196.50 while Salix stock tumbled $1.90 to $155.96.
Valeant to buy Salix
February 23, 2015 at 12:08 PM EST